Mutational Analysis of the Ligand-Binding Domain of M-T2 Protein, the Tumor Necrosis Factor Receptor Homologue of Myxoma Virus

Journal of Immunology

Volumn 157, Issue 10, 1996, Pages 4486-4495

  Schreiber, Martha ^a   McFadden, Grant ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ALBERTA ENVIRONMENT AND PARKS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS PROTEIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL LINE; CERCOPITHECUS; DRUG ANTAGONISM; EPITOPE MAPPING; GENE VECTOR; GENETICS; GLYCOSYLATION; METABOLISM; METHODOLOGY; MYXOMA VIRUS; NUCLEOTIDE SEQUENCE; VACCINIA VIRUS;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; DNA MUTATIONAL ANALYSIS; EPITOPE MAPPING; GENETIC VECTORS; GLYCOSYLATION; LIGANDS; MYXOMA VIRUS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; VACCINIA VIRUS; VIRAL PROTEINS;

EID: 0030588633     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Moss, B. 1990. Poxviridae and their replication. In Virology, Vol. 2. B. N. Fields and D. M. Knipe, eds. Raven Press, New York, pp. 2079-2111.
2. Fenner, F., and F. N. Ratcliffe. 1965. Myxomatosis. Cambridge University Press, Cambridge.
3. Russell, R. J., and S. J. Robbins. 1989. Cloning and molecular characterization of the myxoma virus genome. Virology 170:147.
4. Turner, P. C., and R. W. Moyer. 1990. The molecular pathogenesis of poxviruses. Curr. Top. Microbiol. Immunol. 163:125.
5. Traktman, P. 1990. Poxviruses: an emerging portrait of biological strategy. Cell 62:621.
6. Buller, R. M. L., and G. J. Palumbo. 1991. Poxvirus pathogenesis. Microbiol. Rev. 55:80.
7. McFadden, G. 1988. Poxviruses of rabbits. In Virus Diseases in Laboratory and Captive Animals. G. Darai, ed. Martinus Nijhoff, Boston, pp. 37-62.
8. McFadden, G. 1994. Rabbit, hare, squirrel and swine poxviruses. In Encyclopedia of Virology. R. Webster and A. Granoff, eds. Academic Press, San Diego, pp. 1153-1160.
9. McFadden, G., and K. Graham. 1994. Modulation of cytokine networks by poxviruses: the myxoma virus model. Semin. Virol. 5:421.
10. McFadden, G., K. Graham, K. Ellison, M. Barry, J. Macen, M. Schreiber, K. Mossman, P. Nash, A. Lalani, and H. Everett. 1995. Interruption of cytokine networks by poxviruses: lessons from myxoma virus. J. Leukocyte Biol. 57:731.
11. Opgenorth, A., K. Graham, N. Nation, D. Strayer, and G. McFadden. 1992. Deletion analysis of two tandemly arranged virulence genes in myxoma virus. M11L and myxoma growth factor. J. Virol. 66:4720.
12. Macen, J. L., C. Upton, N. Nation, and G. McFadden. 1993. SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology 195:348.
13. Upton, C., K. Mossman, and G. McFadden. 1992. Encoding of a homolog of the IFN-γ receptor by myxoma virus. Science 258:1369.
14. Mossman, K., P. Nation, J. Macen, M. Garbutt, A. Lucas, and G. McFadden. 1996. Myxoma virus, M-T7, a secreted homolog of the interferon-γ receptor, is a critical virulence factor for the development of myxomatosis in European rabbits. Virology 215:17.
15. Upton, C., J. L. Macen, M. Schreiber, and G. McFadden. 1991. Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. Virology 184:370.
16. Schreiber, M., K. Rajarathnam, and G. McFadden. 1996. Myxoma virus T2 protein, a tumor necrosis factor (TNF)-receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNFα but the dimer is a more potent TNF inhibitor. J. Biol. Chem. 271:13333.
17. Boshkov, L. K., J. L. Macen, and G. McFadden. 1992. Virus-induced loss of class I MHC antigens from the surface of cells infected with myxoma virus and malignant rabbit fibroma virus. J. Immunol. 148:881.
18. + T lymphocytes. J. Virol 69:5243.
19. Graham, K. A., A. Opgenorth, C. Upton, and G. McFadden. 1992. Myxoma virus M11L ORF encodes a protein for which cell surface localization is critical in manifestation of viral virulence. Virology 191:112.
20. Macen, J. L., K. A. Graham, S. F. Lee, M. Schreiber, L. K. Boshkov, and G. McFadden. 1996. Expression of the myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes. Virology 218:232.
21. Wong, G. H. W., A. Kamb, and D. V. Goeddel. 1992. Antiviral properties of TNF. In Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. B. Beutler, ed. Raven Press, New York, pp. 371-381.
22. Aderka, D., D. Novick, T. Hahn, D. G. Fischer, and D. Wallach. 1985. Increase of vulnerability to lymphotoxin in cells infected by vesicular stomatitis virus and its further augmentation by interferon. Cell. Immunol. 92:218.
23. Koff, W. C., and A. V. Fann. 1986. Human tumour necrosis factor-α kills herpesvirus-infected cells but not normal cells. Lymphokine Res. 5:215.
24. Lorence, R. M., P. A. Rood, and K. W. Kelley. 1988. Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-α and augmentation of its cytotoxicity. J. Natl. Cancer Inst. 80:1305.
25. Wong, G. H. W., and D. V. Goeddel. 1986. Tumour necrosis factors α and β inhibit virus replication and synergize with interferons. Nature 323:819.
26. Sambhi, S. K., M. R. J. Kohonin-Corish, and I. A. Ramshaw. 1991. Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc. Natl. Acad. Sci. USA 88: 4025.
27. Lidbury, B. A., I. A. Ramshaw, and S. K. Sambhi. 1995. The role for host-immune factors in the in vivo antiviral effects of tumour necrosis factor. Cytokine 7:157.
28. Wold, W. S., T. W. Hermiston, and A. E. Tollefson. 1994. Adenovirus proteins that subvert host defenses. Trends Microbiol. 2:437.
29. Smith, C. A., T. Davis, J. Wignall, W. Din, T. Farrah, C. Upton, G. McFadden, and R. Goodwin. 1991. T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor. Biochem. Biophys. Res. Commun. 176:335.
30. Massung, R. F., L.-i. Liu, J. Qi, J. Knight, T. Yuran, A. R. Kerlavage, J. Parsons, J. C. Venter, and J. Esposito. 1994. Analysis of the complete genome of smallpox variola major virus strain Bangladesh-1975. Virology 201:215.
31. Hu, F.-Q., C. A. Smith, and D. J. Pickup. 1994. Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. Virology 204:343.
32. Goebel, S. J., G. Johnson, M. Perkus, S. Davis, J. Winslow, and E. Paoletti. 1990. The complete DNA sequence of vaccinia virus. Virology 179:247.
33. Howard, S., Y. S. Chan, and G. Smith. 1991. Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family. Virology 180:633.
34. Schreiber, M., and G. McFadden. 1994. The myxoma virus TNF-receptor homologue (T2) inhibits tumor necrosis factor-α in a species specific fashion. Virology 204:692.
35. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
36. Davison, A. J., and B. Moss. 1990. New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucleic Acids Res. 18:4285.
37. Bar-Nun, S., and J. M. Gershoni. 1994. Protein-blot analysis of glycoproteins and lectin overlays. In Cell Biology: A Laboratory Manual, Vol. 3. Academic Press, San Diego, pp. 323-331.
38. Branch, D. R., A. Shah, and L. Guilbert. 1991. A specific and reliable bioassay for the detection of femtomolar levels of human and murine tumor necrosis factors. J. Immunol. Methods 143:251.
39. Lis, H., and N. Sharon. 1993. Protein glycosylation: structural and functional aspects. Eur. J. Biochem. 218:1.
40. Opdenakker, G., P. Rudd, C. Ponting, and R. Dwek. 1993. Concepts and principles of glycobiology. FASEB J. 7:1330.
41. Kornfeld, R., and S. Kornfeld. 1985. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54:631.
42. Opdenakker, G., P. Rudd, M. Wormald, R. A. Dwek, and J. Van Damme. 1995. Cells regulate the activities of cytokines by glycosylation. FASEB J. 9:453.
43. Hounsell, E., and M. J. Davies. 1993. Role of protein glycosylation in immune regulation. Ann. Rheum. Dis. 52:S22.
44. Corcoran, A. E., K. Barrett, M. Turner, A. Brown, A.-M. Kissonerghis, M. Gadnell, P. Gray, Y. Chernajovsky, and M. Feldman. 1994. Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor: involvement of individual cysteine-rich repeats. Eur. J. Biochem. 223:831.
45. Marsters, S. A., A. D. Frutkin, N. J. Simpson, B. M. Fendly, and A. Ashkenazi. 1992. Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding. J. Biol. Chem. 267:5747.
46. Scallon, B. J., H. Trinh, M. Nedelman, F. Brennan, M. Feldmann, and J. Ghrayeb. 1995. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. Cytokine 7:759.
47. Hsu, K., and M. V. Chao. 1993. Differential expression and ligand binding properties of tumor necrosis factor receptor chimeric mutants. J. Biol. Chem. 268: 16430.
48. Yan, H., and M. V. Chao. 1991. Disruption of cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding. J. Biol. Chem. 266: 12099.
49. Banner, D., A. D'Arcy, W. Janes, R. Gentz, H.-J. Schoenfeld, C. Broger, H. Loetscher, and W. Lesslauer. 1993. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation. Cell 73:431.